Nexiguran Ziclumeran Gene Editing: A Pioneering Treatment for Hereditary ATTR with Polyneuropathy

Study Background and Disease Burden

Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, progressive, and fatal multisystem disease characterized by the extracellular deposition of misfolded transthyretin (TTR) amyloid fibrils, primarily affecting peripheral nerves. This leads to debilitating sensorimotor and autonomic polyneuropathy, significantly impairing quality of life and survival. Conventional therapies have limitations in halting disease progression and are often accompanied by treatment burdens. Consequently, there remains a pressing clinical need for disease-modifying therapies with the potential to sustainably suppress TTR production and mitigate amyloid deposition.

Nexiguran ziclumeran (nex-z), an investigational in vivo genome editing agent, utilizes CRISPR-Cas9 technology to selectively inactivate the TTR gene in hepatocytes, the primary source of systemic TTR. This novel approach aims to deliver a one-time infusion for rapid, durable TTR suppression, differentiating it from RNA interference or antisense oligonucleotide therapies that require repeated administration.